[HIV/TB co-infection in rural settings of Benin: case of the Djougou-Ouake-Copargo sanitary district (north-west Benin)]. / Co-infection VIH/Tuberculose en milieu rural au Benin: cas de la zone sanitaire Djougou-Ouake-Copargo (nord-ouest Benin).

AIMS: we measured the burden of TB/HIV co-infection in a rural setting of Benin, and assessed the outcome of tuberculosis treatment at the end of the intensive phase of TB treatment. METHODS: This is a retrospective, cross-sectional, descriptive study, covering January 2006 to December 2011. RESULTS: A total of 256 patients were included, 67 (26.1%) were HIV +. A minority, 25% of co-infected HIV / PTB, had TB bacilli high density (+++) versus 45% of mono-infected (P = 0.005). The smear conversion was obtained in 96% of coinfected versus 93% in HIV- at the end of the intensive phase (P = 0.5). The cure rate was 86% and 93.1% respectively in co-infected and HIV-. A proportion of 13.5% of co-infected died versus 3% in HIV- (P = 0.005). 21% of co-infected with CD4 <200 died versus 3.6% of those with CD4> 200 (P = 0.041). CONCLUSION: This work underlines the high prevalence of HIV / TB co-infection in this region. Co-infected patients respond well to treatment, but their mortality is high when they are very immunocompromised.

BUTS: nous avons mesuré le fardeau que constitue la co-infection VIH/ tuberculose chez des tuberculeux en milieu rural au Bénin ; et évaluer l'issue du traitement antituberculeux à la fin de la phase intensive. MÉTHODES: Il s'agit d'une étude transversale rétrospective, descriptive couvrant Janvier 2006 à Décembre 2011. RÉSULTATS: Au total 256 patients ont été colligés, 67 (26,1%) étaient VIH+. Une proportion de 25 % des co-infectés VIH/TPM+ avaient une densité bacillaire à trois croix (+++) contre 45% des tuberculeux VIH- (P=0,005). La négativation de la bacilloscopie était obtenue chez 96% des patients co-infectés contre 93% chez les tuberculeux VIH- à la fin de la phase intensive (P=0,5). Le taux de guérison était respectivement de 86% et 93,1% chez les co-infectés et les non VIH. Une proportion de 13,5% des co-infectés étaient décédés contre 3% chez les VIH- (P=0,005). 21% des co-infectés ayant un CD4<200 étaient décédés contre 3,6% de ceux dont le CD4>200 (P=0,041). CONCLUSION: Ce travail souligne la forte prévalence de l'infection par le VIH chez les tuberculeux de cette région. Les co-infectés répondent bien au traitement, mais leur taux de mortalité est plus élevé, surtout s'ils sont très immunodéprimés.

[HIV/TB co-infection in rural settings of benin: case of Djougou-Ouake-Copargo district (north-west Benin]. / Co-infection VIH/Tuberculose en milieu rural au benin: cas de la zone sanitaire Djougou-Ouake-Copargo (Nord-ouest Benin).

AIMS: We measured the burden of HIV/tuberculosis (HIV/TB) co-infection in people infected by TB in rural settings of Benin, and assessed the outcome of TB treatment at the end of the intensive phase. METHODS: This is a retrospective, cross-sectional, descriptive study, covering January 2006 to December 2011. RESULTS: A total of 256 patients were gathered, 67 (26.1%) were HIV +. A proportion of 25% of co-infected HIV / PTB had TB bacilli high density (+++) versus 45% of mono-infected (P = 0.005). The smear conversion was obtained in 96% of coinfected versus 93% in HIV- at the end of the intensive phase (P = 0.5). The cure rate was 86% and 93.1% respectively in co-infected and HIV-. A proportion of 13.5% of co-infected died versus 3% in HIV- (P = 0.005). 21% of co-infected with CD4 <200 died versus 3.6% of those with CD4> 200 (P = 0.041). CONCLUSION: This work underlines the high prevalence of HIV / TB co-infection in this region. Co-infected patients respond well to treatment, but their mortality is high when they are very immunocopromissed.

BUTS: Nous avons mesuré le fardeau que constitue la co-infection VIH/ tuberculose chez des tuberculeux en milieu rural au Bénin; et évaluer l'issue du traitement antituberculeux à la fin de la phase intensive. MÉTHODES: Il s'agit d'une étude transversale rétrospective, descriptive couvrant Janvier 2006 à Décembre 2011. RÉSULTATS: Au total 256 patients ont été colligés, 67 (26,1%) étaient VIH+. Une proportion de 25 % des co-infectés VIH/TPM+ avaient une densité bacillaire à trois croix (+++) contre 45% des tuberculeux VIH- (P=0,005). La négativation de la bacilloscopie était obtenue chez 96% des patients co-infectés contre 93% chez les tuberculeux VIH- à la fin de la phase intensive (P=0,5). Le taux de guérison était respectivement de 86% et 93,1% chez les co-infectés et les non VIH. Une proportion de 13,5% des co-infectés étaient décédés contre 3% chez les VIH- (P=0,005). 21% des co-infectés ayant un CD4<200 étaient décédés contre 3,6% de ceux dont le CD4>200 (P=0,041). CONCLUSION: Ce travail souligne la forte prévalence de l'infection par le VIH chez les tuberculeux de cette région. Les co-infectés répondent bien au traitement, mais leur taux de mortalité est plus élevé, surtout s'ils sont très immunodéprimés.

Prevalence of latent TB infection in HIV infected persons in the Sylvanus Olympio teaching hospital of Lomé.

OBJECTIVE: Determine the prevalence of latent TB infection in HIV-infected people. METHOD: Using a cross-sectional study on HIV-infected persons monitored in the Department of Lung and Infectious Diseases of CHU Sylvanus Olympio of Lomé from August 10, 2010 to November 10, 2010. All patients are receiving anti-retroviral therapy and have no clinical or radiological symptoms of TB, and had never received tuberculin skin test (TST) in the last 3months. The CD4 rate of all patients was more than 200cells/µl. The diagnosis of latent TB infection is based on the measurement of at least 5mm of skin induration, 72h after a subcutaneous injection of 5IU of purified tuberculin. RESULTS: One hundred and fifty four persons were included in the study, of which 107 were female and 47 were male. The median age was 40years old. Eleven patients were exposed to a risk of TB and only 70.7% of patients had a BCG scar. A suspicion of former TB was found in 18.8% of patients and approximately 45% of patients were very immunocompromised with a CD4 rate between 200 and 350; 117 patients had a positive TST. This represents an overall prevalence of 76% of latent TB infection. CONCLUSION: The prevalence of latent TB infection obtained with the TST is high in this study. A similar study using the interferon-gamma release assay, which is more specific, would be more helpful to obtain more reliable epidemiological data on patient outcomes and to determine the appropriateness of the use of chemoprophylaxis with isoniazid.

[Becoming new pulmonary tuberculosis patients with sputum smear-positive at the end of second month of anti tubercular treatment in Lome]. / Devenir des nouveaux patients tuberculeux pulmonaires a bacilloscopie positive a la fin du deuxieme mois de traitement antituberculeux a Lome.

AIMS: To determine the frequency of the new smear-positive pulmonary tuberculosis patients at the end of the second month of anti-tuberculosis treatment and to analyze the outcomes of their treatment. PATIENTS AND METHOD: It was a retrospective comparative study from January 2006 to June 2008, based on the analysis of the records and treatment cards from the diagnosis and treatment centers of Lome. New sputum smear-positive tuberculosis patients at the end of the second month (smear positive 2 months) constituted the study population. A comparison group consisted of the new tuberculosis patients with sputum smear-negative at the end of the second month (negative smear 2 months). RESULTS: The proportion of sputum smear-positive at 2 months was 5.34% (163/3050). Cure and failure rates were respectively 69.3% and 17.2% for smear-positive 2 months versus 79.1% and 3.7% for control group. The death rate was similar in both groups (3% and 3.7%). CONCLUSION: The smear positive 2 month's patients have a high risk of failure and must receive special attention during their follow-up to improve the results of treatment.

BUT: Déterminer la fréquence des nouveaux patients tuberculeux pulmonaire à bacilloscopie positive à la fin du 2ème mois de traitement antituberculeux et analyser les résultats de leur traitement. PATIENTS ET MÉTHODE: Il s'agissait d'une étude rétrospective comparative de janvier 2006 à juin 2008, basée sur l'analyse des registres et les cartes de traitement de tuberculose des centres de diagnostic et de traitement de Lomé. Les nouveaux patients tuberculeux à bacilloscopie positive à la fin du deuxième mois (frottis mois 2 positif) constituaient la population de l'étude. Un groupe de comparaison était constitué avec les nouveaux patients tuberculeux à bacilloscopie négatif à la fin du deuxième mois (frottis mois 2 négatif). RÉSULTATS: La proportion des frottis mois 2 positif était de 5,34 % (163/3050). Les taux de guérison et d'échec étaient respectivement de 69,3% et de 17,2% chez les frottis 2 positif contre 79,1% et 3,7 % chez les frottis 2 négatif. Le taux de décès était similaire dans les deux groupes (respectivement 3% et 3,7%). CONCLUSION: Les patients à frottis 2 positif ont un risque élevé d'échec et doivent bénéficier d'une attention particulière au cours de leur suivi afin améliorer les résultats de leur traitement.

Prevalence des neuropathies peripheriques (NP) et leurs facteurs associes chez les patients sous traitement antiretroviral suivis dans le service des maladies infectieuses du CHU Sylvanus Olympio de Lome

Objectifs: Evaluer la prevalence des neuropathies peripheriques et leurs facteurs associes. Methode: Il s'agit d'une etude transversale menee du 1er fevrier au 1er juillet 2011 sur l'ensemble des patients recevant un traitement antiretroviral associant deux inhibiteurs nucleosidiques et un inhibiteur non nucleosidique de la reverse transcriptase. Le diagnostic des neuropathies peripheriques a ete pose sur la base de criteres cliniques. Les facteurs associes etaient representes par l'existence de facteurs de risque connu comme cause de neuropathies peripheriques. La numeration des lymphocytes T CD4 a ete effectuee chez tous les patients.Resultats : L'etude a porte sur 512 personnes. Parmi eux; 157 (30;7) presentaient des neuropathies peripheriques a type de paresthesies (75;2); les sensations de brulure (44;6); les douleurs franches (42;7). L'age avance; l'alcoolisme; l'immunodepression avancee et l'exposition a la stavudine etaient les facteurs. Conclusion : L'incrimination de la Stavudine dans la survenue de cette maladie justifie son retrait des protocoles ARV de premiere ligne

[Sputum smear conversion during intensive TB treatment phase according to HIV status, in hospitalised patients in Togo]. / Négativation des frottis respiratoires selon le statut VIH à la phase intensive du traitement antituberculeux chez les patients hospitalisés au Togo.

METHOD: We prospectively studied patients with pulmonary TB, with or without HIV-1 co-infection, from December 1, 2007 to December 1, 2008. Two groups of patients naive for TB and antiretroviral treatment (group A: 96 co-infected TB/HIV and group B: 171 TB infected but HIV negative) were selected randomly. The CD4 count was assessed according to HIV status, and all patients received RHEZ TB treatment for 2 months. Pulmonary smear was assessed at two weeks, four weeks, six weeks, and eight weeks. RESULT: Two hundred and sixty seven patients were treated (26.6% of admissions). The mean age was 34.62 ± 11 years and the sex ratio was 1.3. A proportion of 35.75% patients were HIV co-infected with a median CD4 count at 157 cells per millimeter cube. The sputum smear conversion was obtained for more than 87.5% of patients in group A and 24.56% in group B at two weeks; 94% of patients in group A and 61.83% in group B at four weeks; 100% of patients in group A and 87.33% in group B at six weeks, and 100% of patients in group A and 96.77% in group B at eight weeks. P<0.05 at six weeks. CONCLUSION: HIV infected TB patients were more susceptible to treatment than TB/HIV infected patients in the first six weeks.

[Prevalence of HIV-TB co-infection and impact of HIV infection on pulmonary tuberculosis outcome in Togo]. / Prévalence de la co-infection VIH-tuberculose et impact de l'infection VIH sur l'évolution de la tuberculose pulmonaire au Togo.

The aim of this study was to determine the prevalence of HIV infection in tuberculosis patients and its impact on the TB treatment. We enrolled 569 pulmonary TB patients in four diagnosis and treatment centres in Togo. All patients were new TB cases and received the first-line TB drugs: two months of rifampicin-pyrazinamide-isoniazid-ethambutol and six months of isoniazid-ethambutol. HIV testing was done according to the national guidelines, using rapid diagnosis tests. The CD4 lymphocyte counting was performed by Facscalibur (BD, Sciences) for all HIV-positive patients. Of the 569 TB patients enrolled, 135 (23.7%) were HIV positive (TB/HIV+). HIV prevalence was 22.4% (76 of 339) among men and 25.6% (59 of 230) among women without statistical difference. The global rate of treatment success was 82.2%. The rate of treatment success was lower (64.3%) in TB/HIV+ patients than in TB/HIV- patients (87.5%) (p <0.01). The mortality rates were 25.6% and 11.8% in TB/HIV+ patients and TB/HIV- patients, respectively, with a statistically significant difference (p <0.01). We did not found any statistical difference between the rates of treatment success among TB/HIV- (87.5%) patients and TB/HIV+ patients who had TCD4 lymphocyte counts above 200/µl (84.4%). TB program in Togo must take into account HIV infection to improve its performance.

[Evaluation of asthma care in Africa]. / Evaluation de la prise en charge de l'asthme en Afrique.

BACKGROUND: Despite international recommendations, asthma is still considered as a condition that is not perfectly managed. This was the first study performed in Togo to access asthma management among physicians. OBJECTIVE: To evaluate the attitude of physicians and internes in the management of asthma in Togo. Methods Descriptive survey through auto-questionnaire conducted among physicians and internes on 1st through 31st march 2005. The studied population was 159 physicians who at least managed once an asthma patient. Computerized data were the initial complementary check up in asthma patients, the prescription habit during and between acute periods, the knowledge of the technical procedure of metered-dose inhaled devices, the using of peak-flow meter and prescription of sport. Data analysis was performed with Epi 2002 software. RESULTS: Participation rate was 78%. The peak-flow meter wasn't known by the investigated physicians and was prescribed by only 14.5% of them. Chest X-ray (97.5%) and hemogram (91.2%) were the most prescribed analysis. For the management of acute periods of asthma, beta 2 agonists were prescribed especially for inhaled route or for drips often combined with corticosteroïds. Between acute periods, aerosol of beta 2 agonists were prescribed with corticosteroïds (metered-dose aerosol and tablets). Dry powders were not known. Physicians in Togo forbade sport in 44%. CONCLUSION: Asthma management is not correctly done in Togo.

[Tetanus and HIV: a fortuitous association?]. / Tétanos et VIH : une association fortuite ?

OBJECTIVES: To describe the relation between HIV infection and tetanus. METHODS: This prospective study includes all patients admitted to our infectious diseases department with tetanus between July 15 and December 31, 2007, who underwent screening for HIV-1 and 2. RESULTS: The study included 21 patients (sex-ratio = 9.5). Their mean age was 37 years (SD: 5.3) were included. Nine patients (42%) had been immunized, but never received a booster dose. The portal of entry was found in 16 patients (76%) - all but one a skin injury. Tetanus was generalized in all patients (Mollaret classification: 76% Stage II, 24% stage III). Twelve (57%) patients were infected with HIV. Their mean CD4 cell count was 157/mm3 (SD: 75/mm3, range: 74-232/mm3). The overall mortality rate was 53%. It was 100% when no portal of entry was found. It was significantly higher among HIV-positive than HIV-negative patients (82 versus 18%). It did not, however, differ significantly between HIV-positive subjects with a CD4 count < 200/mm3 and those with a CD4 count > or = 200 (58 versus 42%). CONCLUSION: HIV and the absence of portal of entry are poor prognostic factors in tetanus. Therefore, a revision of the Dakar International Classification on tetanus should be revised, to score as 1 those patients with HIV infection and no portal of entry.

[Intrathecal therapy with 1 500 UI of antitetanic serum and 1.5 g of intravenous metronidazole: prognosis of tetanus in hospitalized patients in Togo]. / Intérêt de la thérapie intrathécale à 1 500 UI de sérum antitétanique combinée à 1,5 gramme de métronidazole en intraveineux sur le pronostic du tétanos en milieu hospitalier togolais.

OBJECTIVE: To determine the effect on clinical progression and mortality during tetanus of intrathecal therapy with 1 500 IU of heterologous antitetanus serum administered with 1.5 g of intravenous metronidazole. METHOD: This prospective study took place from August 1, 2006, to June 30, 2007, and included two groups of patients randomly allocated to treatment by two different techniques. The test group of 17 patients received 1 500 IU of antitetanus heterologous immunoglobulin by the intrathecal route as well as 1.5 g of intravenous metronidazole daily. The control group of 25 patients received the standard treatment of 9 000 IU of heterologous antitetanic serum administered half (4 500 IU) cutaneously and half intramuscularly. Clinical manifestations and mortality were assessed. Mollaret's classification and the Dakar prognosis score were used to classify patients according to severity. RESULTS: Forty-two patients were treated. Their mean age was 29.44 years (standard deviation: 18.3 years) and the M/F sex ratio was 5. Skin wounds accounted for 57.1% of the portals of entry, deep wounds for 26.2%; the rest were unknown. Twenty patients (47.6%) had fever when admitted. Tetanus was generalized in all cases and 76.2% of patients were stage III. Four patients were HIV-positive. Clinical improvement, defined as a decrease in dysphagia, trismus, and paroxysm, was observed more quickly in the test group: 48 hours after treatment began, improvement was seen in more than 76% of the test group compared with 28% in the control group. In the test group, the mean hospitalization period was 7.4 days and mortality was 11.7%, compared with 19 days and a mortality rate of 52% in the control group. CONCLUSION: Prevention through vaccination appears to be the long-term solution for the eradication of tetanus. In the meantime, we can hope for a better clinical response with intrathecal therapy of 1 500 IU of heterologous antitetanus serum and 1.5 g of intravenous metronidazole daily.

[Smoking among journalists in the private and public media in Togo]. / Tabagisme dans les médias publics et privés du Togo.

BACKGROUND: Collaboration with journalists should help to reduce the tobacco epidemic. All over the world, no study assessed the extent of tobacco smoking in the bosom of reporters. OBJECTIVE: To determine the prevalence of tobacco smoking among reporters and to evaluate their attitudes towards tobacco. MATERIALS AND METHODS: A cross-sectional survey using an anonymised questionnaire was conducted among reporters working for both the public and private media in Togo between the 1st May and the 31st June 2005 using the "from door to door" method. Data analysis was performed with Epi-Info 3.3.2. RESULTS: The participation rate was 82.44%. The prevalence of tobacco smoking was 25%. Smoking was more common in men (26.1% versus 19.6%, p=0.03). The average age that subjects had started to smoke was 17.1 years (Range: 6 and 30 years) with all smokers reporting that they smoked tobacco only in the form of cigarettes. 79.3% of smokers thought that they would quit within the next five years. Only 6.2% reporters often talked about smoking while on the microphone. A majority of the reporters approved of anti-smoking initiatives. CONCLUSION: Because of their importance in the diffusion of news, the media must be enrolled in the fight against tobacco.

Attitudes of private pharmacists in the management of asthma patients in Lomé.

BACKGROUND: Optimal asthma management requires interventions by a number of health professionals, including pharmacists. OBJECTIVE: To assess the attitudes of pharmacists towards asthma patients and to evaluate their knowledge about how to use the metered dose inhaler. METHODS: A descriptive survey through self-administered questionnaire was conducted among pharmacists in private pharmacies in Lomé, Togo. Pharmacists who did not respond before the sixth round of the investigator were excluded from the study. RESULTS: The participation rate was 76.4%. All pharmacists stated that asthma patients visited their pharmacies during and/or between acute episodes. Some asthma patients visited the pharmacies without prior medical prescription. Asthma drugs were delivered without medical prescription, particularly during acute episodes. In case of acute episodes, care was provided by 51.2% of pharmacists. Aerosol devices were the most widely used treatment, although the technical procedures required for correct inhalation were found to be poorly understood by 27.4% of the pharmacists. Pharmacists provided recommendations to patients on long-term treatment, regular medical follow-up and avoidance of allergens and tobacco smoking. CONCLUSION: Rather than limiting their action to dispensing drugs, pharmacists can also become involved in educating asthma patients.

Prevalence of symptoms of asthma, rhinitis and eczema in 13- to 14-year-old children in Africa: the International Study of Asthma and Allergies in Childhood Phase III.

Phase I of the International Study of Asthma and Allergies in Childhood has provided valuable information regarding international prevalence patterns and potential risk factors in the development of asthma, allergic rhinoconjunctivitis and eczema. However, in Phase I, only six African countries were involved (Algeria, Tunisia, Morocco, Kenya, South Africa and Ethiopia). Phase III, conducted 5-6 years later, enrolled 22 centres in 16 countries including the majority of the centres involved in Phase I and new centres in Morocco, Tunisia, Democratic Republic of Congo, Togo, Sudan, Cameroon, Gabon, Reunion Island and South Africa. There were considerable variations between the various centres of Africa in the prevalence of the main symptoms of the three conditions: wheeze (4.0-21.5%), allergic rhinoconjunctivitis (7.2-27.3%) and eczema (4.7-23.0%). There was a large variation both between countries and between centres in the same country. Several centres, including Cape Town (20.3%), Polokwane (18.0%), Reunion Island (21.5%), Brazzaville (19.9%), Nairobi (18.0%), Urban Ivory Coast (19.3%) and Conakry (18.6%) showed relatively high asthma symptom prevalences, similar to those in western Europe. There were also a number of centres showing high symptom prevalences for allergic rhinoconjunctivitis (Cape Town, Reunion Island, Brazzaville, Eldoret, Urban Ivory Coast, Conakry, Casablanca, Wilays of Algiers, Sousse and Eldoret) and eczema (Brazzaville, Eldoret, Addis Ababa, Urban Ivory Coast, Conakry, Marrakech and Casablanca).

[Incidence and impact of HIV infection among patients with bacterial pleurisy in Lomé (Togo)]. / Fréquence et impact de l'infection au virus de l'immunodéficience humaine chez les patients souffrant de pleurésies bactériennes à Lomé (Togo).

A prospective study was made in the Tokoin university hospital in Lomé (Togo) to determine the incidence and the impact of HIV among patients with bacterial pleurisy. Two hundred cases of bacterial pleurisy were consecutively included over 17 months. The HIV diagnostic was performed using ELISA (Vironostika HIV Uni-Form II plus O and HIV1 and 2 Bispot Immunocomb II). The 200 cases of pleurisy included 152 (76%) tuberculous pleural effusion and 48 (24%) pleural empyema. Staphylococcus aureus (32%), Streptococcus pneumoniae (14.9%), and Pseudomonas (14.9%) were the main causes of pleural empyema. The HIV incidence was 61% (122/200). The mortality rate ranged from 26.2% in the HIV positive group to 5.1% in HIV negative group (P = 0.0001). The bacterial aspect of pleural empyema was heterogeneous in both groups but Salmonella Enteritidis and Salmonella Typhimurium were identified only among patients with HIV.

[Recurrent varicella and HIV infection. Apropos of 10 cases seen in Lomé]. / Varicelle récurrente et infection par le VIH. A propos de 10 cas observés à Lomé.

Herpes-zoster is commonly observed in immunodepressed patients with HIV infection in Africa. It is due to reactivation of the varicella-zoster virus. Varicella which is usually considered as the acute invasive phase of infection can recur in the same subject during immunodepression, thus constituting recurrent varicella. Little information is available concerning recurrent varicella in Africa. The purpose of the present report is to describe 10 cases observed in 9 adults and 1 child in Lomé, Togo. In 6 cases recurrence of varicella allowed diagnosis of HIV infection. Clinical symptoms were severe with widespread lesions and fever-related changes in general status. Nine of the 10 patients required hospitalization. In all cases the illness lasted more than 3 weeks. This series demonstrates that varicella in adults can be the first clinical manifestation of HIV infection in tropical areas and that this possibility should be investigated especially if varicella is recurrent.

Le prurigo au cours du SIDA en milieu hospitalier a Lome

Une etude prospective a ete menee; durant 13 mois; afin de determiner la prevalence et les caracteristiques cliniques et evolutifs du prurigo au cours du SIDA en milieu hospitalier a Lome. 40 des 120 patients atteints du SIDA (33;33 pour cent) examines au cours de cette periode souffraient de prurigo. Entre 1 et 3 mois d'evolution du SIDA; la frequence etait de 53;84 pour cent; contre 26;66 pour cent apres 1 an d'evolution. Cliniquement le purit etait feroce et constant chez tous les patients; dans 31 cas le prurigo etait generalise. L'evolution a ete indefiniment chronique dans tous les cas. Cette etude confirme que le prurigo est une affection tres prevalente au cours du SIDA en zone tropicale. Sa connaissance par tous les praticiens; devrait contribuer au depistage precose de l'infection a VIH en Afrique

[Pulmonary abscess in Lomé. Apropos of 144 cases collected in the Pneumo-Phthisiology Department of the University Hospital Center-Tokoin from 1981-1993]. / Abcès pulmonaires à Lomé. A propos de 144 cas colligés dans le service de pneumo-phtisiologie du CHU-Tokoin de 1981 à 1993.

The authors report the results of a retrospective study of 144 cases of lung abscess observed in the Pneumo-Phthisiology Department of Tokoin University Teaching Hospital of Lomé (Togo) between 1981 and 1993 for to determine epidemiological, clinical, therapeutical and evolutive aspects of this affection on West Africa. The results like those of other authors confirm still grievous evolution nowadays of lung abscess in spite of medical drugs efficacy.